NIH NATIONAL CANCER INSTITUTE

CATALYTICALLY HYPERACTIVE VARIANT OF HUMAN APOBEC3G PROTEIN

SUMMARY (1024-CHARACTER LIMIT)

The National Cancer Institute (NCI) seeks co-development and licensing interest to further develop and optimize APOBEC3G protein variants.

NIH REFERENCE NUMBER

E-150-2018

PRODUCT TYPE

- Therapeutics

KEYWORDS

- APOBEC3G, ssDNA, AIDS, Gene Editing, CTD2, Genetically disordered diseases, Matsuo

COLLABORATION OPPORTUNITY

This invention is available for licensing and co-development.

CONTACT

- John D. Hewes
  NCI - National Cancer Institute

  240-276-5515

  John.Hewes@nih.gov

STATUS

Active

DESCRIPTION OF TECHNOLOGY

Researchers at the National Cancer Institute (NCI) have developed a highly active variant of the catalytic domain APOBEC3G with higher ssDNA affinity. This variant may be used to develop therapeutics for AIDS, and may also be used as a tool of gene editing techniques. This hyperactive variant of the human APOBEC3G protein (hereby called CTD2) can be used as a tool to edit human genes in combination with the CRISPR/Cas9 system. CTD2 is selective to a specific target DNA sequence, soluble, and catalytically hyperactive, which makes CTD2 the ideal molecule to use in the aforementioned gene editing, using the CRISPR/Cas9 system.

Figure: Antiviral restriction activity of FLAG-NTD-CTD2







POTENTIAL COMMERCIAL APPLICATIONS

- Therapeutic for HIV
- Gene Editing

COMPETITIVE ADVANTAGES

- The variant of the catalytic domain of APOBEC3G has high affinity to ssDNA substrates as apparent dissociation constant, Kd, is 55 μM
- The variant of the catalytic domain of APOBEC3G can catalyze deamination of cytosines in single stranded DNA 20 times faster than the wild type catalytic domain of APOBEC3G
- The variant of the catalytic domain of APOBEC3G is 4 times more soluble than the wild type catalytic domain of APOBEC3G

INVENTOR(S)

Hiroshi Matsuo Ph.D. (NCI)

PUBLICATIONS

Maiti A, et al. Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA. [PMID 29941968]

PATENT STATUS

- **U.S. Provisional:** U.S. Provisional Patent Application Number 62/673,591 , Filed 18 May 2018

THERAPEUTIC AREA

- Infectious Diseases